{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"0"}]}],"title":"On-treatment deaths include post-treatment survival follow-up deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"0"}]}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"On-treatment deaths, which include post-treatment survival follow-up deaths, were collected during the post-infusion period (starting at the day of first infusion) until the end of the study, approx. 60 months.\n\nAll deaths refers to the sum of on-treatment deaths and post-treatment survival follow-up deaths up to approx. 60 months.","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"NUMBER","populationDescription":"Clinical Database Population: all infused participants in the Main cohort","reportingStatus":"POSTED","timeFrame":"On-treatment deaths: Up to 60 months; Post-treatment survival follow-up deaths: Up to approx. 60 months","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}